Arya Pharma (Pty) Ltd的争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 1 条

2026
南非卫生产品监管局下令召回四批Enalapril 10mg Arya
宣布召回
南非卫生产品监管局（Sahpra）在上市后检查发现不符合规格的结果后，下令召回四批高血压药物Enalapril 10mg Arya。此次召回被列为II类A级，由Arya Pharma (Pty) Ltd与Sahpra协商实施。患者、医护人员、药房、批发商及其他供应商被敦促检查库存并停止分发受影响批次。
当事方说明的目的. 保护患者并保障公众健康
品牌回应
- 召回 — Arya Pharma (Pty) Ltd
  Sahpra said the recall is classified as a Class II-Type A recall and is being implemented by Arya Pharma (Pty) Ltd in consultation with Sahpra in accordance with the Medicines and Related Substances Act 101 of 1965 as amended.
来源摘录
- The recall follows post‑marketing inspections that flagged out‑of‑specification results, prompting urgent action to protect patients and safeguard public health.
- Sahpra said the recall is classified as a Class II-Type A recall and is being implemented by Arya Pharma (Pty) Ltd in consultation with Sahpra in accordance with the Medicines and Related Substances Act 101 of 1965 as amended.
来源